A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1759

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG: MGL-3196
DRUG: Placebo
PROCEDURE: Liver Biopsy

Sponsor

Madrigal Pharmaceuticals, Inc.